J&J/Achillion Partnership Offers Fast Track To Six-Week HCV Treatment
This article was originally published in The Pink Sheet Daily
Executive Summary
In equity-based deal, Achillion stresses that Olysio’s presence in the market could help get one or more of its candidates to market more quickly. Firms will study triple therapy pairing Olysio with ACH-3102 and other candidates.